Compare NTR & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTR | PODD |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6B | 22.1B |
| IPO Year | N/A | 2007 |
| Metric | NTR | PODD |
|---|---|---|
| Price | $62.40 | $291.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 19 |
| Target Price | $64.00 | ★ $366.58 |
| AVG Volume (30 Days) | ★ 2.9M | 805.5K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.50% | N/A |
| EPS Growth | ★ 150.34 | N/A |
| EPS | ★ 3.70 | 3.45 |
| Revenue | ★ $25,671,000,000.00 | $2,521,800,000.00 |
| Revenue This Year | $6.44 | $32.55 |
| Revenue Next Year | $1.26 | $20.39 |
| P/E Ratio | ★ $16.64 | $83.93 |
| Revenue Growth | 0.45 | ★ 27.11 |
| 52 Week Low | $43.70 | $230.05 |
| 52 Week High | $65.08 | $354.88 |
| Indicator | NTR | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 60.60 | 38.05 |
| Support Level | $61.42 | $287.52 |
| Resistance Level | $63.78 | $299.22 |
| Average True Range (ATR) | 1.53 | 8.42 |
| MACD | 0.26 | -1.25 |
| Stochastic Oscillator | 76.02 | 13.46 |
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients—nitrogen, potash, and phosphate—although its main focus is potash, where it is the global leader in installed capacity with a roughly 20% market share. The company is also the largest agricultural retailer in North America and Australia, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.